Helsinki: The European Chemicals Agency sits on two committee opinions that will decide how Europe treats an entire chemical family, and the law those opinions feed into has not been written yet. That sequencing problem now defines the PFAS restriction file, the largest single restriction dossier ever filed under European chemicals law.
The dossier began in 2023, when Denmark, Germany, the Netherlands, Norway and Sweden jointly proposed a restriction covering more than ten thousand per- and polyfluoroalkyl substances. Three years of evaluation followed. ECHA’s Committee for Risk Assessment closed its work in March 2026 and backed an EU-wide restriction. The Committee for Socio-Economic Analysis published a draft opinion in the same direction and ran a consultation that closed in May. The agency expects to transmit both opinions to the Commission around the turn of the year.
What happens next depends on machinery that is running late. The revision of REACH, the regulation that gives any restriction its legal architecture, slipped from February 2025 to the second half of 2026 after the Regulatory Scrutiny Board rejected the Commission’s impact assessment in September 2025. A restriction decision therefore arrives while the underlying rulebook is still being rewritten.
Why the sequence matters more than the science
Regulators rarely enjoy the luxury of finishing one file before starting the next, but the order here carries consequences. A restriction adopted under current REACH articles inherits the current derogation logic, the current enforcement powers and the current registration duties. If the revision changes any of those in 2027, the PFAS measure either gets retrofitted or sits awkwardly beside a reformed regime.
Industry has read that risk clearly. Chemical producers argue that a restriction covering thousands of substances at once should wait for a reformed law that can handle grouping properly. Environmental groups counter that every year of delay adds persistent compounds to soil and water that no future law can remove. Both arguments describe the same gap. Neither resolves it.
The evidence base itself is not seriously contested. PFAS compounds resist degradation, travel through water systems and accumulate in blood serum across the European population. National monitoring programmes in Germany, France and the Nordic states have detected them in drinking water sources well beyond industrial sites. The scientific committees did not dispute persistence. They spent three years on the harder question of which uses genuinely lack substitutes.
The derogation map is the real decision
That question produces the operational answer. Fluoropolymer seals in chemical plants, membranes in electrolysers, refrigerants and certain medical devices have no drop-in replacements at industrial scale today. Semiconductor fabrication uses PFAS in photolithography. Each of those uses will likely receive a time-limited derogation, and the length of each derogation matters more to companies than the headline restriction does.
Consumer applications face a different calculation. Textile coatings, cosmetics, food packaging and ski wax have viable alternatives already on the market, and several member states moved ahead of Brussels with national bans. Denmark restricted PFAS in food contact materials in 2020. France legislated on cosmetics and textiles in 2025. That national activity creates exactly the fragmentation a single European restriction exists to prevent.
Companies planning capital spending now face a wide range of possible outcomes. A restriction with twelve-year derogations for industrial uses looks very different from one with five-year derogations, and the difference lands on investment decisions being taken this autumn for plants that will run into the 2040s.
The Commission holds the pen once the opinions arrive. It drafts the restriction text, sends it to the REACH Committee of member state representatives, then to Parliament and Council scrutiny. Realistically, adoption falls in 2027 and transition periods run from 2029. That timetable gives the revised REACH regulation a chance to catch up, provided the impact assessment clears the Scrutiny Board on its second attempt.
The broader lesson concerns how Europe handles chemical families rather than individual substances. Regulating one compound at a time invited substitution into near-identical molecules with the same persistence. Grouping thousands of substances answers that problem but strains a legal framework built for single-substance decisions. The PFAS file is the stress test, and the results arrive before the framework has been repaired.





